Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Enhanced liver targeting of 5-fluorouracil using galactosylated human serum albumin as a carrier molecule
Author: Cai, C.
Zhou, K.
Wu, Y.
Linyan Wu, L.
Citation: Journal of Drug Targeting, 2006; 14(2):55-61
Publisher: Harwood Acad Publ GMBH
Issue Date: 2006
ISSN: 1061-186X
Statement of
Chun Cai‌, Keyuan Zhou‌, Yong Wu‌ and Linyan Wu
Abstract: The objective of this study was to develop a liver-specific antihepatocarcinoma agent. The galactosylated human serum albumin 5-fluorouracil conjugate (GHSA-5-FU) was prepared and tested for its chemical characteristic, biodistribution and primary cytotoxicity. The matrix assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF-MS) was applied to determined the molar ratio (moles of 5-FU/mole of G-HSA and moles of galactose/mole of HSA) of the conjugate. The liver targeting ability of GHSA-5-FU labeled by 131I was evaluated by measuring the total radioactivity in organs after i.v. administration in mice and rabbits, and the cytotoxicity of the conjugate was assayed by MTT method. The results showed that the molar ratio of galactose to HSA was 50, and the 5-FU to GHSA was 15. Liver uptake in rabbits and mice peaked within 5–20 min after injection. The radioactivity (counts/g tissue) of the conjugate in the liver was several times higher than those in the other organs. The conjugate showed strong cytotoxicity, but no significant cytotoxicity difference was found between GHSA-5-FU and free 5-FU.
DOI: 10.1080/10611860600613324
Published version:
Appears in Collections:Aurora harvest 5
Obstetrics and Gynaecology publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.